Kidney International Reports最新文献

{"title":"20 Years Iranian Experience of Organ Donation: Shifting From Compensated Living Unrelated Kidney Transplantation","authors":"Ali Nobakht Haghighi , Omid Ghobadi , Katayoun Najafizadeh , Feridoun Noohi , Behrooz Broumand , Iraj Fazel","doi":"10.1016/j.ekir.2025.01.032","DOIUrl":"10.1016/j.ekir.2025.01.032","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 979-982"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discordant Results Between Creatinine- and Cystatin C-based Equations for Estimating GFR","authors":"Pierre Delanaye ,&nbsp;Martin Flamant ,&nbsp;Emmanuelle Vidal-Petiot ,&nbsp;Jonas Björk ,&nbsp;Ulf Nyman ,&nbsp;Anders Grubb ,&nbsp;Stephan J.L. Bakker ,&nbsp;Martin H. de Borst ,&nbsp;Marco van Londen ,&nbsp;Laurence Derain-Dubourg ,&nbsp;Andrew D. Rule ,&nbsp;Björn O. Eriksen ,&nbsp;Toralf Melsom ,&nbsp;Per-Ola Sundin ,&nbsp;Natalie Ebert ,&nbsp;Elke Schaeffner ,&nbsp;Magnus Hansson ,&nbsp;Karin Littmann ,&nbsp;Anders Larsson ,&nbsp;Thomas Stehlé ,&nbsp;Hans Pottel","doi":"10.1016/j.ekir.2025.01.030","DOIUrl":"10.1016/j.ekir.2025.01.030","url":null,"abstract":"<div><h3>Introduction</h3><div>Discordant results between cystatin C and creatinine in estimating glomerular filtration rate (GFR) are an important medical issue. However, the equation that should be used when GFR estimates are discordant remains unclear.</div></div><div><h3>Methods</h3><div>This cross-sectional analysis included 15,485 participants with GFR measured by the clearance of an exogenous marker, serum creatinine, and cystatin C. We studied the proportion of discordant results defined as an absolute (&gt; 15 ml/min per 1.73 m²) or relative (&gt; 20%) difference between creatinine-based estimated GFR (eGFR, eGFR_crea) and cystatin C–based eGFR (eGFR_cys) using different equations (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI], European Kidney Function Consortium [EKFC], and reexpressed Lund-Malmö [r-LMR]). We also researched for the best estimating equations to be used in subjects with concordant or discordant results to estimate measured GFR (mGFR).</div></div><div><h3>Results</h3><div>In the total cohort, the proportion of subjects with discordant results (absolute or relative) was larger for CKD-EPI (35.1 and 40.6%) than for EKFC (21.9 and 31.7%) or r-LMR (22.8 and 32.8%) equations. Among discrepant results, the proportion of eGFR_cys &lt; eGFR_crea was significantly higher than the proportion of eGFR_crea &lt; eGFR_cys for the CKD-EPI equations, whereas the occurrence of discrepancy was similar in the 2 discrepant groups for EKFC or r-LMR. For the EKFC and r-LMR equations, but not for the CKD-EPI, the equation combining creatinine and cystatin C was consistently the closest to the mGFR in the discrepant groups.</div></div><div><h3>Conclusion</h3><div>Based on the lower discrepancy proportion, better balance between eGFR_crea and eGFR_cys, and better concordance with mGFR, the EKFC, and r-LMR equations should be preferred over the CKD-EPI to estimate GFR.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1248-1259"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Blood Pressure in High-Risk Patients With CKD Using an Interdisciplinary Remote Hypertension Program","authors":"Molly C. Fisher ,&nbsp;Sharon Rikin ,&nbsp;Sonali Gupta ,&nbsp;Jeremy Awori ,&nbsp;Michel Terzibachi ,&nbsp;Gracy Sebastian ,&nbsp;Allison Stark ,&nbsp;Tanya S. Johns","doi":"10.1016/j.ekir.2025.01.028","DOIUrl":"10.1016/j.ekir.2025.01.028","url":null,"abstract":"<div><h3>Introduction</h3><div>Interventions are needed to reduce racial and ethnic disparities in achieving blood pressure (BP) control among patients with chronic kidney disease (CKD). We determined the feasibility and effectiveness of an interdisciplinary remote patient monitoring (RPM) hypertension program in predominantly Black and Hispanic patients with CKD.</div></div><div><h3>Methods</h3><div>We evaluated an RPM hypertension program for patients with CKD in a New York City health system between July 2021 and October 2022. BP data were transmitted in real-time using a cellular-enabled BP device. Education on lifestyle and adherence was provided, and medications were adjusted by a nurse practitioner (NP) via telemedicine. Feasibility was quantitatively assessed as enrollment, participation, and retention at 3 months. Effect on BP was estimated as mean change in BP at 3 months and proportion with BP &lt; 130/80 mmHg at 6 months.</div></div><div><h3>Results</h3><div>Among 111 patients invited, 102 (91.9%) enrolled and 87 (78.4%) were retained in the program for 3 months. Median age was 61 years, 50% were female, 55.9% were Black, 35.3% were Hispanic, and median estimated glomerular filtration rate was 47.5 ml/min per 1.73 m². The median days per month that BP was measured ranged from 16 to 23. Mean change in systolic and diastolic BP from enrollment to 3 months was −15.0 ± 20.8 (<em>P</em> &lt; 0.0001) and −6.7 ± 17.7 (<em>P</em> = 0.0007), respectively. By 6 months, 49.4% achieved BP &lt; 130/80 mm Hg.</div></div><div><h3>Conclusion</h3><div>This RPM hypertension program in patients with CKD was feasible and effective in improving BP, which is promising for increasing equity in hypertension control. Future studies evaluating long-term maintenance of BP control using this approach compared with usual care are needed.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1101-1110"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD","authors":"Bernard Chan ,&nbsp;Amanda Varghese ,&nbsp;Sunil V. Badve ,&nbsp;Roberto Pecoits-Filho ,&nbsp;Murilo Guedes ,&nbsp;Clare Arnott ,&nbsp;Rebecca Kozor ,&nbsp;Emma O’Lone ,&nbsp;Min Jun ,&nbsp;Sradha Kotwal ,&nbsp;Geoffrey A. Block ,&nbsp;Glenn M. Chertow ,&nbsp;Scott D. Solomon ,&nbsp;Muthiah Vaduganathan ,&nbsp;Vlado Perkovic ,&nbsp;Brendon L. Neuen","doi":"10.1016/j.ekir.2025.01.029","DOIUrl":"10.1016/j.ekir.2025.01.029","url":null,"abstract":"<div><h3>Introduction</h3><div>Heart failure and chronic kidney disease (CKD) are closely associated, and iron deficiency is highly prevalent in both conditions. However, major cardiovascular and nephrology guidelines offer contrasting recommendations for iron use. We evaluated the effects of iron versus usual care or placebo on the clinical outcomes in patients with CKD.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of randomized trials on i.v. or oral iron in patients with CKD (PROSPERO CRD42023453468). We searched Medline, Embase, and the Cochrane Register from database inception until February 1, 2024 to identify eligible trials. We determined the overall results and stratified them by dialysis- and nondialysis-requiring CKD using random effects models, with certainty of evidence assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach. The primary composite endpoint was hospitalization for heart failure or cardiovascular death.</div></div><div><h3>Results</h3><div>We identified 45 trials that met the inclusion criteria. Compared with usual care or placebo, iron reduced the risk of the primary composite endpoint (1659 events; risk ratio [RR]: 0.84, 95% confidence interval [CI]: 0.75–0.94; moderate certainty), an effect consistent across dialysis and nondialysis requiring CKD (<em>P</em>-heterogeneity = 0.70). The effect on the primary endpoint appeared driven by both components of hospitalization for heart failure (RR: 0.77; 95% CI: 0.61–0.96; moderate certainty) and cardiovascular death (RR: 0.81; 95% CI: 0.65–1.02; low certainty). The incidence of serious adverse events was lower for iron compared with usual care or placebo (RR: 0.90, 95% CI: 0.82–0.98; moderate certainty; <em>P</em>-heterogeneity = 0.09).</div></div><div><h3>Conclusion</h3><div>Iron therapy may reduce the risk of heart failure and cardiovascular death in patients with CKD. Randomized trials evaluating the effects of iron on clinical outcomes are needed, especially in nondialysis patients with CKD with or without anemia.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1037-1049"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Building Interventional Nephrology Skills in India: A Decade-Long Journey by the AVATAR Foundation","authors":"Sanjiv Jasuja ,&nbsp;Vivekananda Jha ,&nbsp;Devinder S. Rana ,&nbsp;Gaurav Sagar ,&nbsp;Maurizio Gallieni ,&nbsp;Anupam Bahl ,&nbsp;Tushar J. Vachharajani","doi":"10.1016/j.ekir.2025.02.020","DOIUrl":"10.1016/j.ekir.2025.02.020","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 983-987"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients","authors":"Li Wang ,&nbsp;Li Zuo ,&nbsp;Ming Shi ,&nbsp;Leyi Gu ,&nbsp;Kunling Ma ,&nbsp;Pei Wang ,&nbsp;Yu Wang ,&nbsp;Qun Luo ,&nbsp;Menghua Chen ,&nbsp;Ping Zhang ,&nbsp;Hongli Jiang ,&nbsp;Guisen Li ,&nbsp;Weifeng Zhang ,&nbsp;Yingxue Cathy Liu ,&nbsp;Qing Zhao","doi":"10.1016/j.ekir.2025.01.038","DOIUrl":"10.1016/j.ekir.2025.01.038","url":null,"abstract":"<div><h3>Introduction</h3><div>Hyperphosphatemia in patients undergoing dialysis is not well-controlled. AP306 is a pan-inhibitor of phosphate transporters, designed to block the active uptake of phosphate through the gastrointestinal tract.</div></div><div><h3>Methods</h3><div>In this phase 2 randomized, active-controlled, open-label study, hemodialysis patients with serum phosphate between 5.5 and 9.0 mg/dl were randomized to receive either AP306 or sevelamer carbonate for 12 weeks. The primary outcome was the change in serum phosphate levels from baseline until the therapy ceased. AP306 was initiated at 75 mg and adjusted stepwise to 125 mg and 150 mg orally thrice daily every 4 weeks, to maintain serum phosphate between 3.5 and 5.5 mg/dl. Sevelamer levels were adjusted using the same criteria and frequency.</div></div><div><h3>Results</h3><div>A total of 27 patients were randomized to receive AP306 and 28 to receive sevelamer. At the end-of-treatment, both AP306 and sevelamer resulted in a significant decrease from baseline in serum phosphate by 2.51 mg/dl (95% confidence interval [CI]:−3.07 to −1.92; <em>P</em> &lt; 0.001) and 1.08 mg/dl (95% CI: −1.58 to −0.59), respectively. The proportions of patients achieving the recommended range as per the Kidney Disease: Improving Global Outcomes guidelines (2.5–4.5 mg/dl) were about 20% higher in AP306 than in sevelamer, starting from treatment week 5. The most reported adverse events (AEs) associated with AP306 were gastrointestinal disorders (51.9%), most of which were mild to moderate diarrhea (44.4%).</div></div><div><h3>Conclusion</h3><div>AP306 monotherapy significantly reduced serum phosphate levels and substantially improved the serum phosphate control rate in hemodialysis patients with hyperphosphatemia. AP306 was safe and well-tolerated.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1143-1151"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotype-Phenotype Correlations in Denys-Drash Syndrome in Children","authors":"Mathilde Glénisson ,&nbsp;Mathilde Grapin ,&nbsp;Thomas Blanc ,&nbsp;Evgenia Preka ,&nbsp;Julien Hogan ,&nbsp;Manon Aurelle ,&nbsp;Gwenaëlle Roussey ,&nbsp;Antoine Mouche ,&nbsp;Caroline Rousset-Rouviere ,&nbsp;Robert Novo ,&nbsp;Camille Faudeux ,&nbsp;Marc Fila ,&nbsp;Isabelle Vrillon ,&nbsp;Sylvie Cloarec ,&nbsp;Thomas Simon ,&nbsp;Jérôme Harambat ,&nbsp;Edouard Martinez Casado ,&nbsp;Julien Rod ,&nbsp;Morgane Carre Lecoindre ,&nbsp;Laurence Heidet ,&nbsp;Sabine Sarnacki","doi":"10.1016/j.ekir.2025.01.014","DOIUrl":"10.1016/j.ekir.2025.01.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Denys-Drash syndrome (DDS) is a rare disease typically associated with a triad of early onset nephrotic syndromes (NS), susceptibility to Wilms tumor (WT), and genitourinary structural defects. DDS is caused by Wilms’ tumor suppression gene (<em>WT1</em>) variants, with the most frequent variants in exons 8 and 9. This study aimed to evaluate the long-term clinical outcomes and genotype-to-phenotype correlations in a large, multicenter cohort of children with typical DDS.</div></div><div><h3>Methods</h3><div>We conducted a national retrospective study of all children diagnosed with a pathogenic variant in <em>WT1</em> exons 8 or 9 in France between 2000 and 2022.</div></div><div><h3>Results</h3><div>Fifty-eight children with DDS and variants in exons 8 (<em>n</em> = 23) and 9 (<em>n</em> = 35) of the <em>WT1</em> gene were identified. Half of the children presented with NS (57% congenital, median age at presentation 0.3 years [interquartile range, IQR: 0.0–0.6]). Twenty-nine percent of children developed WT at a median age of 1.2 (0.5–2.2) years. Children with a variant in exon 8 developed NS much earlier than those with a variant in exon 9 (<em>P</em> = 0.0048), regardless of the type of genetic variation, leading to earlyier kidney failure (KF) (0.3 vs.1.4 years respectively; <em>P</em> = 0.0001) and higher mortality (35% vs 9%, <em>P</em> = 0.02). More than 90% of the truncating variants were located in exon 9 and were significantly associated with the occurrence of WT compared with the DNA-binding-site variants (<em>P</em> &lt; 0.0015).</div></div><div><h3>Conclusion</h3><div>In our cohort, children’s DDS clinical trajectory was associated with exon localization. In the era of genomic newborn screening, depicting genetic risk is of utmost importance for personalized patient care.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1205-1212"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts","authors":"Sean J. Barbour ,&nbsp;Rosanna Coppo ,&nbsp;Jonathan Barratt ,&nbsp;Lee Er ,&nbsp;Richard Lafayette ,&nbsp;Hiddo J.L. Heerspink ,&nbsp;Dana V. Rizk ,&nbsp;Adrian Liew ,&nbsp;Vivekanand Jha ,&nbsp;Hong Zhang ,&nbsp;Yusuke Suzuki ,&nbsp;Hernan Trimarchi ,&nbsp;Daniel C. Cattran ,&nbsp;International IgA Nephropathy Network Research Group","doi":"10.1016/j.ekir.2025.01.025","DOIUrl":"10.1016/j.ekir.2025.01.025","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1283-1287"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flow-Cytometric Quantification of Urine Kidney Epithelial Cells Specifically Reflects Tubular Damage in Acute Kidney Diseases","authors":"Leonie Wagner ,&nbsp;Jacob Kujat ,&nbsp;Valerie Langhans ,&nbsp;Luka Prskalo ,&nbsp;Diana Metzke ,&nbsp;Emil Grothgar ,&nbsp;Paul Freund ,&nbsp;Nina Goerlich ,&nbsp;Hannah Brand ,&nbsp;Sara Timm ,&nbsp;Matthias Ochs ,&nbsp;Andreas Grützkau ,&nbsp;Sabine Baumgart ,&nbsp;Christopher M. Skopnik ,&nbsp;Adrian Schreiber ,&nbsp;Falk Hiepe ,&nbsp;Gabriela Riemekasten ,&nbsp;Philipp Enghard ,&nbsp;Jan Klocke","doi":"10.1016/j.ekir.2025.01.037","DOIUrl":"10.1016/j.ekir.2025.01.037","url":null,"abstract":"<div><h3>Introduction</h3><div>Tubular injury is one of the main mechanisms driving acute kidney injury (AKI); however, clinicians still have a limited diagnostic repertoire to precisely monitor damage to tubular epithelial cells (TECs). In our previous study, we used single-cell sequencing to identify TEC subsets as the main components of the urine signature of AKI. This study aimed to establish TECs as clinical markers of tubular damage.</div></div><div><h3>Methods</h3><div>A total of 243 patients were analyzed. For sequencing, we collected 8 urine samples from patients with AKI and glomerular disease. We developed a protocol for the flow cytometric quantification of CD10/CD13⁺ proximal TECs (PTECs) and CD227/CD326⁺ distal TECs (DTECs) in urine by aligning urinary single-cell transcriptomes and TEC surface proteins using Cellular Indexing of Transcriptome and Epitope Sequencing (CITE-Seq). Marker combinations were confirmed in kidney biopsies. We validated our approach in 4 cohorts of 235 patients as follows: patients with AKI (<em>n</em> = 63), COVID-19 infection (<em>n</em> = 47), antineutrophil cytoplasmic autoantibody (ANCA)–associated vasculitis (AAV) with active disease or stable remission (<em>n</em> = 110), and healthy controls (<em>n</em> = 15).</div></div><div><h3>Results</h3><div>Our findings demonstrated that CD10/CD13 and CD227/CD326 adequately identified PTECs and DTECs, respectively. Distal urinary TEC counts correlate with the severity of AKI based on Kidney Disease: Improving Global Outcomes (KDIGO) stage and acute estimated glomerular filtration rate (GFR) loss in 2 separate cohorts and can successfully discriminate AKI from healthy controls and glomerular disease.</div></div><div><h3>Conclusion</h3><div>We propose that urinary CD227/CD326⁺ TEC count is a specific, noninvasive marker for tubular injury in AKI. Our protocol provides a basis for a deeper phenotypic analysis of urinary TECs.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1260-1273"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Terminal Complement Deficiency in Israeli Bedouins With Kidney Failure","authors":"Guy Chowers ,&nbsp;Dror Ben-Ruby ,&nbsp;Danit Atias-Varon ,&nbsp;Omer Shlomovitz ,&nbsp;Keren Slabodnik-Kaner ,&nbsp;Maayan Kagan ,&nbsp;Shany Avayou ,&nbsp;Elvira Romanjuk ,&nbsp;Boris Rogachev ,&nbsp;Yosef S. Haviv ,&nbsp;Ohad S. Birk ,&nbsp;Noam Hadar ,&nbsp;Younes Bathish ,&nbsp;Iris Barshack ,&nbsp;Alexander Volkov ,&nbsp;Camila Avivi ,&nbsp;Anna Pavlovsky ,&nbsp;Orly Haskin ,&nbsp;Amos J. Simon ,&nbsp;Efrat Glick-Saar ,&nbsp;Asaf Vivante","doi":"10.1016/j.ekir.2025.01.019","DOIUrl":"10.1016/j.ekir.2025.01.019","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1274-1278"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}